The Follow-up After Shorter Tapes Study. Effectiveness and Safety of Shorter Trans-obturator Tapes. (FAST)

December 9, 2024 updated by: Kjersti Rimstad, University Hospital, Akershus

The FAST- Study: The Follow-up After Shorter Tapes Study Effectiveness and Safety of Shorter Trans-obturator Tapes: A Prospective Observational Study From the Norwegian Female Incontinence Registry

Urinary incontinence after pregnancy and labor affects 1 in 3 women and has a negative impact on quality of life (QOL), limiting women's physical activity and impairing sexual function. The traditional surgical method treating female urinary incontinence is to implant a sub-urethral synthetic sling, the currently preferred method in Norway. The majority of women treated with synthetic slings obtain great improvement in QOL, but a few experience severe complications including chronic pelvic pain. Several countries, therefore, have reverted to older, less effective surgical methods to avoid synthetic material. Awareness of severe complications has, in some Norwegian hospitals, led to a shift in technique towards shorter slings. With shorter slings, the goal is to achieve the same grade of continence as traditional slings, but with fewer serious complications. The long-term results and complications of these shorter slings are mostly unknown. Akershus University Hospital (AHUS) shifted to shorter slings early, in 2009, using a single incision mini-sling (SIMS) Ajust. Due to costs, AHUS changed to the intermediate sling TVT-O Abbrevo in 2016.

Through this study, we hope to establish if shorter slings have the same long-term results as traditional slings, and to investigate if shorter slings are safer than traditional slings, with less long-term complications, such as chronic pelvic pain. We plan to perform a long-term follow-up of women having had surgery with shorter slings at AHUS.

All patients operated with either SIMS Ajust or TVT-O Abbrevo at AHUS between 2009 and 2020 will be invited to a long-term follow-up. The study participants will be asked to fill in validated questionnaires regarding symptoms of urine leakage, QOL, any chronic pain related to the surgery, debut of pain, level of pain and any treatments for the pain. All women treated with the current used sling Abbrevo is invited to a physical examination including testing of their voiding function and a gynecologic examination to check for complications.

2D- and 3D ultrasound scans will be done on the TVT-O Abbrevo group to evaluate the position-, attachment- and any misplacement of the sling.

Women experiencing insufficient long-term results, such as chronic pain, will be offered a full examination and treatment.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Background:

Stress Urinary incontinence (SUI) is a frequent consequence of childbirth and affects 1/3 of the general female population. It gravely diminishes the quality of life of numerous women by limiting their ability to be physically active, and impairing their sexual function. Mid-urethral sling (MUS) procedures have been the dominant surgical treatment for SUI over the last two decades. The traditional MUS procedures places a polypropylene mesh for support under the urethra, either in front of the bladder passing through the pelvis to the lower abdomen (tension free vaginal tape (TVT)), or to the side of the pelvis in the groin area (tension-free vaginal tape obturator inside-out (TVT-O)). These traditional techniques have well documented long lasting results and have improved the quality of life in most women with SUI. However, a few women experience serious complications such as severe chronic pain, dyspareunia, erosion/expulsion of the mesh, and voiding dysfunctions. Even though these devastating complications are rare, the consequence for affected women is lifelong reduced quality of life, even if the synthetic material is removed in its entirety. This has led to massive negative publicity, lawsuits against manufacturers and a movement in social media to ban these procedures. Several countries have therefore reverted to older, less effective surgical methods to avoid the use of synthetic materials.

Single incision mini-slings (SIMS), with much less synthetic mesh than traditional slings were introduced worldwide in 2006. In 2010, the TVT-O Abbrevo (TVT-A), an intermediate sling, was introduced hoping to refine the clinical performance of shorter slings. SIMS and intermediate slings have shown promising short-term results, but regarding long-term efficacy and complication rates, there are only a few published studies with small sample sizes. Given that shorter slings could represent a middle ground between the risk of severe complications and a loss of life quality due to untreated urinary incontinence, data on long-term effect and safety of the newer shorter slings is urgently needed. Retrieving such knowledge would make it possible to update surgical guidelines and provide patients considering surgical options with evidence-based recommendations.

Since 1998, Norway has had a compulsory registry of all incontinence surgeries performed in the country, the Norwegian Female Incontinence Registry (NFIR). Akershus University hospitals (AHUS) started already in 2009 using the SIMS Ajust and later intermediate slings as their preferred incontinence procedure. We therefore have a unique possibility to study the long-term results and complication rates by inviting women back to a long-term follow-up having undergone SIMS and intermediate sling surgery at AHUS. This follow-up also provides the possibility of investigating sling position using 2D dynamic and 3D trans-perineal ultrasound (TPUS). AHUS has the expertise in advanced ultrasound within the research group. How positioning of intermediate slings under the urethra may affect long-term success rates and adverse events is largely unknown. This lack of knowledge makes it difficult for gynecologists evaluating patients in need of repeat surgery, due to either treatment failure or long-term complications. Understanding the biomechanical effects visualized by ultrasound of the increasingly popular shorter slings would enable researchers and doctors to develop the treatment techniques for female incontinence further.

Research questions and methodology:

Part 2. Our over-all aim is to evaluate long-term subjective and objective outcomes of shorter slings.

Study design: Prospective observational study Long-term subjective outcomes Study population: Women treated with SIMS Ajust (n = 744) at Akershus University Hospital between 2009 and 2016 and Intermediate sling TVT-A (n= 318) at Akershus University Hospital between 2016 and 2020.

Follow-up: Potential study participants for both groups will be identified in the local quality database for female incontinence surgery (local NFIR) at AHUS and invited to a long-term follow-up (4-14 years) with questionnaires. The following questionnaires will be sent electronically to the patients together with study invitation and consent form: The validated NFIR questionnaire, the validated Pelvic Floor Impact Questionnaire (PFIQ-7) as well as additional questions regarding pain.

Primary outcomes: Long-term subjective cure rate. Secondary outcomes: Long-term treatment satisfaction scores, quality of life score and complication rates.

Long-term objective outcomes Study population: The 318 women having been treated with the currently most used shorter sling (TVT-A) at AHUS between 2016 and 2020 will be invited to a physical follow-up were they will undergo a clinical examination including assessment of objective cure, sling erosions and development of pelvic organ prolapse using the POP-Q system.

Primary outcomes: Long-term objective cure rates. Secondary outcomes: The same as defined under 1) Long-term subjective outcomes.

Part 3. We will study the positioning of the shorter sling TVT-A under the urethra using dynamic 2D and 3D ultrasound.

Our aim is to study the association between sling position, tension and anchoring under the urethra, and subjective and objective cure rate, and long-term complication rates, especially chronic pelvic pain.

Study design: Prospective observational study Study population: 318 women having had surgery with the intermediate sling TVT-A at AHUS between 2016 and 2020.

Follow-up: Women who consent to study participation and attend the physical follow-up will undergo a clinical examination that includes a transperineal ultrasound (TPUS) examination in the dorsal lithotomy position using a 3,5-6 MHz curved array abdominal probe. The TPUS volumes and images will be obtained with an empty bladder at rest and under full Valsalva.

Primary outcomes: Any association between sling position and subjective and objective cure rate and complication rates.

Secondary outcomes: Any association between sling position, tension or anchoring and long-term complications, especially chronic pelvic pain.

Statistics, power and sample size:

Part 2 This is a follow-up study of all women having been operated at AHUS with Ajust or TVT-A in the study period. Power calculations are not feasible as all women having had SIMS Ajust or TVT-A in the study period consenting to study participation will be analysed for subjective outcomes, whereas all women in the TVT-A group consenting to study participation will be analysed for objective outcomes.

Part 3 For the transperineal ultrasound (TPUS) we have estimated that a sample size of 107 is sufficient to draw valid conclusions. For further details on the calculation, please see the full Protocol.

Risk evaluation and countermeasures. The main risk to the project is patient inclusion. To get robust and valid scientific data we are depending on women being willing to participate in the project with clinical examinations and ultrasound measurements. We have estimated that a studyparticipation of 50% is sufficient to draw valid conclusion. For further information on this estimation please see the protocol

User Participation. The project has two user representatives. They have both participated in the planning of the project and given valuable comments in developing the study protocol. Both have agreed to stay on as part of the project group.

Ethical considerations: The Department Head at AHUS, the NFIR Management team, the NFIRs professional council, The Data Protection Officer at AHUS as well as the Regional Committee for Medical and Health Research Ethics in the Southeast of Norway (REC South East) has approved the study. Signed consent will be obtained from all study participants.

Study participants will only be examined using established techniques for the evaluation of women after incontinence surgery, the exception being the 3D ultrasound examination. None of them involves any additional risk for the participants.

Questionnaires and consent forms will be sent electronically and stored at the Services for Sensitive Data (TSD), as well as the research server at AHUS. Study participants who report persistent or recurring incontinence as well as any long-term complications related to the slings will be offered a full new clinical evaluation.

Study Type

Observational

Enrollment (Estimated)

750

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Kjersti Rimstad Rimstad, Cand.Med.
  • Phone Number: +4748159564
  • Email: kjerstri@uio.no

Study Contact Backup

Study Locations

  • Norway
      • Lorenskog, Norway, 1478
        • Recruiting
        • Akershus University Hospital
        • Contact:
          • Kjersti Rimstad Rimstad, Cand. Med.
          • Phone Number: 67960000
          • Email: kjerstri@uio.no

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Female incontinence patients operated at AHUS between 2009 and 2021, aged between 25 and 90.

Description

Inclusion Criteria:

  • All women operated for stress-urinary incontinence with TVT-O Abbrevo of Ajust incontinence sling between 2009 and 2020.

Exclusion Criteria:

  • Women operated with other incontinence operations or slings.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Women operated with shorter incontinence tapes
Women operated at AHUS between 2009 and 2020 for stress urinary incontinence with shorter incontinence tapes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
NFIR questionnaire subjective cure rate
Time Frame: From 2009 to 2020 and evaluation in 2024
Rate of subjective cure defined as a stress urinary incontinence index score <3 estimated by calculating a stress urinary incontinence index score from 4 clusters of questions in the NFIR questionnaire measuring degree of symptom bother from 0 to 12.
From 2009 to 2020 and evaluation in 2024
Objective cure rate on validated NFIR stress test
Time Frame: From 2009 to 2020 and evaluation in 2024.
Objective cure defined as 0g leakage at a cough-jump pad weighing stress test.
From 2009 to 2020 and evaluation in 2024.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
NFIR questionnaire quality of life score
Time Frame: From 2009 to 2020 and evaluation in 2024
Level of quality of life score generated from 4 questions in the NFIR questionnaire measuring QoL impact. This index ranges from 0 (excellent quality of life) to 16 (poor quality of life).
From 2009 to 2020 and evaluation in 2024
Long-term complications
Time Frame: From 2009 to 2020 and evaluation in 2024.
Rate of complications at long-term follow-up clinical examination.
From 2009 to 2020 and evaluation in 2024.
NFIR treatment satisfaction rate
Time Frame: From 2009 to 2020 and evaluation in 2024.
Rate of women answering "very satisfied with treatment" given the options "very satisfied", "moderately satisfied", "neither satisfied nor dissatisfied", "moderately dissatisfied" or "very dissatisfied" in the NFIR questionnaire.
From 2009 to 2020 and evaluation in 2024.
NFIR total complication rate
Time Frame: From 2009 to 2020 and evaluation in 2024.
Total complication rates in the NFIR questionnaire.
From 2009 to 2020 and evaluation in 2024.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Akershus

Investigators

  • Principal Investigator: Anna Marie Ellstrom Engh Professor, PhD, Akershus university hospital HC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 24, 2024

Primary Completion (Estimated)

May 18, 2026

Study Completion (Estimated)

October 31, 2026

Study Registration Dates

First Submitted

December 2, 2024

First Submitted That Met QC Criteria

December 9, 2024

First Posted (Estimated)

December 13, 2024

Study Record Updates

Last Update Posted (Estimated)

December 13, 2024

Last Update Submitted That Met QC Criteria

December 9, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FAST 2 and 3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

We will use anonymized data in our analysis.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress Urinary Incontinence

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe